TPE:6657's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.52 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Energenesis Biomedical Co (TPE:6657) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Energenesis Biomedical Co Forward Dividend Yield % Related Terms
TPE:6657 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Energenesis Biomedical Co (TPE:6657) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Energenesis Biomedical Co and its competitors. According to the industry distribution chart, Energenesis Biomedical Co ranks #999999 out of 145 companies in the Biotechnology industry.
Is Energenesis Biomedical Co's Forward Dividend Yield % too high?
Energenesis Biomedical Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Energenesis Biomedical Co ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Energenesis Biomedical Co in the lower half of its industry. The industry median Forward Dividend Yield % is 1.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.52, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.28, compared to a current price of NT$36.40 — trading 29% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$36.40 is trading 29% below its estimated GF Value™ of NT$51.28.
GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.
Key valuation signals for TPE:6657:
Forward Dividend Yield %: 0.00%
GF Value™: NT$51.28 vs. price of NT$36.40 (29% below fair value)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score
Get the complete analysis for TPE:6657
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 